15, June, 2021, Shenzhen, China—SMOORE, a global leader in offering vaping technology solutions, has entered into a two-year extension of its Material Transfer and Research Agreement with AIM ImmunoTech Inc.(AIM), an immuno-pharma company, so as to continuously develop Ampligen as a potential inhalation therapy for COVID-19 and other respiratory viral diseases, echoing its vision of atomization making life better.
Currently, AIM is planning to conduct Phase 1/2 inhalation clinical study on a parallel track with SMOORE’s device development testing.
SMOORE and AIM have entered into an agreement on April 1, 2020 for the first time, to study the utilization of an innovative SMOORE inhalation delivery device and Ampligen as a potential treatment approach for the SARS-CoV-2 pandemic. Over the past year, SMOORE has focused on the development of a personal inhalation device designed to administer Ampligen, given temperature parameters of dsRNA.
Meanwhile, AIM has studied the safety and efficacy of Ampligen using an ex vivo 3D model in primary human respiratory epithelial cells at Utah State University, which showed that Ampligen was able to decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels, and conducted intranasal safety testing. AIM and SMOORE hope to commence inhalation safety testing before year-end.
“With SMOORE’s concept for an Ampligen inhalation delivery device ready to be developed, and Ampligen’s track record of both safety and efficacy, we believe AIM is well positioned to move forward with our goal of developing Ampligen as a potential inhalation therapy for COVID-19 and potentially other respiratory viral diseases,” said AIM CEO Thomas K. Equels.
“We are happy to partner with AIM to explore applications of advanced atomization technology in medical inhalation therapy,” Dr. Zhiqiang Shi, Chief Scientist and Director of Global R&D of SMOORE, commented. “We will coordinate our device development work along with our partner’s plan and the regulation needs to move into next phase testing on schedule.”
With one of its R&D focus on the application of atomization technology in healthcare and pharmaceutical fields, SMOORE has made satisfying progress in research and development of medical and healthcare atomization products.
Adhering to concentric diversification and technology branding, SMOORE is proactively promoting the application of atomization technology to sectors other than vaping while incubating more atomization technology brands, such as its flagship, FEELM.
SMOORE’s R&D expenditure in 2020 amounted to RMB419,806,000, an increase of approximately 51.3% over the previous year. The company expects to increase its R&D percentage of revenue from 4.2% of 2020 to 10% of 2021. Moreover, its R&D experts account for 46.4% of the total non-production employees.
Underpinned by its technological accumulation in atomization, SMOORE will continue to increase investments in research and development, especially in fundamental researches in relation to product safety, health and consumer experience while actively exploring the application of atomization technology in health, medical and other fields.
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base. The Company is the world’s largest vaping device manufacturer in terms of revenue, accounting for 18.9% of the total global market share. SMOORE is famous for its flagship ceramic atomization technology brand, FEELM, which has been widely recognized by consumers around the world.
FEELM is a high-end atomization technology brand belonging to SMOORE. Focusing on the research of cutting-edge atomization technology, FEELM also specializes in the development and manufacturing of high quality atomization devices driven by FEELM ceramic coil. “FEELM inside” symbol is on the closed-system pods of a number of global leading tobacco companies and independent vaping companies around the world. The accumulated sales volume of FEELM has surpassed 1.2 billion pieces per year.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
FEELM|SMOORE International Holdings Limited